Back to results
US 8,709,719 B2Granted
ZNF217 a new prognostic and predictive biomarker of recurrent invasive and metastatic phenotypes in breast cancer
AssigneesCentre Leon Berard, Universite Claude Bernard Lyon 1
InventorsPascale Cohen, Julie Vendrell, Pierre Roux
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for determining the prognosis of a cancer. The methods involve determining the level of expression of the ZNF217 gene in a cancer cell sample or in a tumor sample wherein over-expression of ZNF217 is correlated with likelihood of metastasis and with likelihood of relapse/recurrence of the cancer.
Claims23
A method for determining the prognosis of a breast cancer in a patient comprising the following steps:
- assaying a tumor sample from the patient for at least one prognostic marker of breast cancer and assessing the level of expression of the ZNF217 gene in said sample;
- and if the sample displays at least one prognostic marker classifying the breast cancer as having a favorable prognosis, re-classifying the breast cancer as having a poor prognosis if the ZNF217 gene is over-expressed in said sample, wherein the level of expression of the ZNF217 gene in the sample is assessed by quantification of the ZNF217 gene transcript(s) by reverse transcription and amplification, wherein the amplification is performed using a combination of primers comprising a first primer as forward primer and a second primer as reverse primer, the first primer comprising the sequence as depicted in SEQ ID NO 1 or the reverse primer comprising the sequence as depicted in SEQ ID NO 2, followed by quantitative detection of the amplicon obtained.
A method for determining the prognosis of a breast cancer in a patient comprising the following steps:
- assaying a tumor sample from said patient for at least one prognostic marker of breast cancer and assessing the level of expression of the ZNF217 gene in the sample;
- and if the sample displays at least one prognostic marker classifying the breast cancer as having a favorable prognosis, re-classifying the breast cancer as having a poor prognosis if the ZNF217 gene is over-expressed in said sample, wherein the level of expression of the ZNF217 gene in the sample is assessed by quantification of the ZNF217 gene transcript(s) by reverse transcription and amplification, wherein the amplification is performed using a combination of primers comprising a first primer as a forward primer and a second primer as a reverse primer, the first primer comprising the sequence as depicted in SEQ ID NO 1 and the second primer comprising the sequence as depicted in SEQ ID NO 2, followed by quantitative detection of the amplicon obtained.
Dependencies are inferred from the claim text.